R6K origin plasmid R6K复制子载体质粒 BioVector NTCC质粒载体菌种细胞基因保藏中心
- 价 格：¥49865
- 货 号：R6K origin
- 产 地：北京
- BioVector NTCC典型培养物保藏中心
- 联系人：Dr.Xu, Biovector NTCC Inc.
电话：400-800-2947 工作微信:1843439339 (QQ同号)
邮件：Biovector@163.com
手机：18901268599
地址：北京
- 已注册
R6K origin plasmid R6K复制子载体质粒
The BioVector's Nanoplasmid vector has shown success for both indirect use ( as for viral vectors and transposons manufacturing) and for direct use, as an effective, safe, and economical preferred vector for gene therapy and manufacturing. It performs favorably compared to legacy (antibiotic resistance) plasmids and more modern alternatives (such as minicircles, midges, MIPs and doggy bones) that are either inefficient or that require cumbersome and costly post-purification processing – and/or are not regulatory compliant (antibiotic-free). In addition, the BioVector's Nanoplasmid’s origin of replication (R6K) has host-restricted replication, compared to traditional plasmids’ promiscuity of replication throughout gram negative hosts. In summary, the Nanoplasmid™ is an ideal non-viral vector for gene therapy of human cells and tissues, offering improved expression and duration of expression, as well as an excellent safety profile, ease and economy of purification. Today, Nanoplasmids are being used by more than 100 gene therapy and immunotherapy organizations worldwide.Higher levels of gene expression than plasmids and minicircles Greater potency, longer duration Demonstrated as safe in multiple clinical trials Low toxicity, in vitro or in vivo Non-promiscuous, replicates only in the BioVector's Nanoplasmid E coli host strain
Supplier来源:BioVector NTCC Inc.
TEL电话:400-800-2947
Website网址: http://www.biovector.net
The BioVector's Nanoplasmid vector has shown success for both indirect use ( as for viral vectors and transposons manufacturing) and for direct use, as an effective, safe, and economical preferred vector for gene therapy and manufacturing. It performs favorably compared to legacy (antibiotic resistance) plasmids and more modern alternatives (such as minicircles, midges, MIPs and doggy bones) that are either inefficient or that require cumbersome and costly post-purification processing – and/or are not regulatory compliant (antibiotic-free). In addition, the BioVector's Nanoplasmid’s origin of replication (R6K) has host-restricted replication, compared to traditional plasmids’ promiscuity of replication throughout gram negative hosts. In summary, the Nanoplasmid™ is an ideal non-viral vector for gene therapy of human cells and tissues, offering improved expression and duration of expression, as well as an excellent safety profile, ease and economy of purification. Today, Nanoplasmids are being used by more than 100 gene therapy and immunotherapy organizations worldwide.Higher levels of gene expression than plasmids and minicircles Greater potency, longer duration Demonstrated as safe in multiple clinical trials Low toxicity, in vitro or in vivo Non-promiscuous, replicates only in the BioVector's Nanoplasmid E coli host strain
Supplier来源:BioVector NTCC Inc.
TEL电话:400-800-2947
Website网址: http://www.biovector.net
- 公告/新闻
